ERYTHROCIN STEARATE

Post-LOE

erythromycin stearate

R-Pharm US

ANDAORALTABLET

Approved

Jun 1964

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

4/8 — Partial

ERYTHROCIN STEARATE (erythromycin stearate) by R-Pharm US is clinical pharmacology orally administered erythromycin base and its salts are readily absorbed in the microbiologically active form. Approved for the following infections caused by chlamydia trachomatis: conjunctivitis of the newborn, pneumonia of infancy, urogenital infections during pregnancy and 5 more indications. First approved in 1964.

Drug data last refreshed 18h ago

$0.0BPart D

Mechanism of Action

CLINICAL PHARMACOLOGY Orally administered erythromycin base and its salts are readily absorbed in the microbiologically active form. Interindividual variations in the absorption of erythromycin are, however, observed, and some patients do not achieve optimal serum levels. Erythromycin is largely…

Worked on ERYTHROCIN STEARATE at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

ERYTHROCIN STEARATE

Mechanism of Action

Indications (8)